Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Nitin Bharat Charbe; Nikhil D. Amnerkar; B. Ramesh; Murtaza M. Tambuwala; Hamid A. Bakshi; Alaa A.a. Aljabali; Saurabh C. Khadse; Rajendran Satheeshkumar; Saurabh Satija; Meenu Metha; Dinesh Kumar Chellappan; Garima Shrivastava; Gaurav Gupta; Poonam Negi; Kamal Dua; Flavia C. Zacconi

doi:10.1016/j.apsb.2020.10.005

Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Nitin Bharat Charbe, Nikhil D. Amnerkar, B. Ramesh, Murtaza M. Tambuwala, Hamid A. Bakshi, Alaa A.a. Aljabali, Saurabh C. Khadse, Rajendran Satheeshkumar, Saurabh Satija, Meenu Metha, Dinesh Kumar Chellappan, Garima Shrivastava, Gaurav Gupta, Poonam Negi, Kamal Dua, Flavia C. Zacconi

Research output: Contribution to journal › Article › peer-review

153 Citations (Scopus)

125 Downloads (Pure)

Abstract

In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies. [Abstract copyright: © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.]

Original language	English
Pages (from-to)	2075-2109
Number of pages	35
Journal	Acta Pharmaceutica Sinica B
Volume	10
Issue number	11
Early online date	13 Oct 2020
DOIs	https://doi.org/10.1016/j.apsb.2020.10.005
Publication status	Published (in print/issue) - 30 Nov 2020

Bibliographical note

Publisher Copyright:
© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

Cancer
Liposomes
Micelles
Nanomedicine
Polymer
Small interfering RNA (siRNA)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.apsb.2020.10.005

1-s2.0-S2211383520307565-mainProof, 2.4 MBLicence: CC BY-NC-ND

https://linkinghub.elsevier.com/retrieve/pii/S2211383520307565

Cite this

Charbe, N. B., Amnerkar, N. D., Ramesh, B., Tambuwala, M. M., Bakshi, H. A., Aljabali, A. A. A., Khadse, S. C., Satheeshkumar, R., Satija, S., Metha, M., Chellappan, D. K., Shrivastava, G., Gupta, G., Negi, P., Dua, K., & Zacconi, F. C. (2020). Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharmaceutica Sinica B, 10(11), 2075-2109. https://doi.org/10.1016/j.apsb.2020.10.005

@article{913c914b0c314ebe9aaac69dddc5be5c,

title = "Small interfering RNA for cancer treatment: overcoming hurdles in delivery",

abstract = "In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies. [Abstract copyright: {\textcopyright} 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.]",

keywords = "Cancer, Liposomes, Micelles, Nanomedicine, Polymer, Small interfering RNA (siRNA)",

author = "Charbe, {Nitin Bharat} and Amnerkar, {Nikhil D.} and B. Ramesh and Tambuwala, {Murtaza M.} and Bakshi, {Hamid A.} and Aljabali, {Alaa A.a.} and Khadse, {Saurabh C.} and Rajendran Satheeshkumar and Saurabh Satija and Meenu Metha and Chellappan, {Dinesh Kumar} and Garima Shrivastava and Gaurav Gupta and Poonam Negi and Kamal Dua and Zacconi, {Flavia C.}",

note = "Publisher Copyright: {\textcopyright} 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = nov,

day = "30",

doi = "10.1016/j.apsb.2020.10.005",

language = "English",

volume = "10",

pages = "2075--2109",

journal = "Acta Pharmaceutica Sinica B",

issn = "2211-3835",

publisher = "Elsevier BV",

number = "11",

}

Charbe, NB, Amnerkar, ND, Ramesh, B, Tambuwala, MM, Bakshi, HA, Aljabali, AAA, Khadse, SC, Satheeshkumar, R, Satija, S, Metha, M, Chellappan, DK, Shrivastava, G, Gupta, G, Negi, P, Dua, K & Zacconi, FC 2020, 'Small interfering RNA for cancer treatment: overcoming hurdles in delivery', Acta Pharmaceutica Sinica B, vol. 10, no. 11, pp. 2075-2109. https://doi.org/10.1016/j.apsb.2020.10.005

TY - JOUR

T1 - Small interfering RNA for cancer treatment: overcoming hurdles in delivery

AU - Charbe, Nitin Bharat

AU - Amnerkar, Nikhil D.

AU - Ramesh, B.

AU - Tambuwala, Murtaza M.

AU - Bakshi, Hamid A.

AU - Aljabali, Alaa A.a.

AU - Khadse, Saurabh C.

AU - Satheeshkumar, Rajendran

AU - Satija, Saurabh

AU - Metha, Meenu

AU - Chellappan, Dinesh Kumar

AU - Shrivastava, Garima

AU - Gupta, Gaurav

AU - Negi, Poonam

AU - Dua, Kamal

AU - Zacconi, Flavia C.

PY - 2020/11/30

Y1 - 2020/11/30

N2 - In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies. [Abstract copyright: © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.]

AB - In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies. [Abstract copyright: © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.]

KW - Cancer

KW - Liposomes

KW - Micelles

KW - Nanomedicine

KW - Polymer

KW - Small interfering RNA (siRNA)

UR - http://www.scopus.com/inward/record.url?scp=85096389438&partnerID=8YFLogxK

U2 - 10.1016/j.apsb.2020.10.005

DO - 10.1016/j.apsb.2020.10.005

M3 - Article

C2 - 33304780

SN - 2211-3835

VL - 10

SP - 2075

EP - 2109

JO - Acta Pharmaceutica Sinica B

JF - Acta Pharmaceutica Sinica B

IS - 11

ER -

Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this